Reuters logo
BRIEF-aTyr Pharma reports signals of clinical activity in genetically distinct Myopathies with Resolaris in exploratory trials
December 13, 2016 / 12:28 PM / 9 months ago

BRIEF-aTyr Pharma reports signals of clinical activity in genetically distinct Myopathies with Resolaris in exploratory trials

Dec 13 (Reuters) - aTyr Pharma Inc -

* Top-Line results from a completed phase 1b/2 trial for adult patients with limb-girdle muscular dystrophy 2b

* Says resolaris continues to demonstrate a generally well tolerated safety profile in all trials

* Reports promising signals of clinical activity in multiple rare genetically distinct myopathies with resolaris in exploratory trials Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below